[CAS NO. 2254693-15-5] SRX3207
PRODUCTS SPECIFICATIONS [2254693-15-5]
DESCRIPTION [2254693-15-5]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 555.65 |
| Molecular Formula | C29H29N7O3S |
| SMILES | O=C1C2=C(C(C3=CC=C(NC4=NC=CC(N5N=C(C)C(CN6CCC6)=C5)=N4)C=C3)=CS2)OC(N7CCOCC7)=C1 |
Summary
IC50 & Target
|
Syk 10.7 nM (IC 50 ) |
PI3Kα 861 nM (IC 50 ) |
PI3Kδ 1280 nM (IC 50 ) |
PI3Kγ 11100 nM (IC 50 ) |
Zap70 1300 nM (IC 50 ) |
In Vitro
In Vivo
SRX3207 (10 mg/kg, orally) increases antitumor immune response [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | LLC or B16 or B16-OVA or CT26 (1 × 10 5 ) cells were injected subcutaneously into syngeneic mice [1] . |
| Dosage: | 10 mg/kg. |
| Administration: | Orally, starting from day 10 when tumors reached 100 mm3 until tumors were harvested on day 21. |
| Result: |
Blocked phosphorylation of Syk at 348 site and Y525/526 site.
Blocked immunosuppressive MΦ polarization. Blocked tumor growth and increased survival effectively. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 5 mg/mL ( 9.00 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.7997 mL | 8.9985 mL | 17.9969 mL |
| 5 mM | 0.3599 mL | 1.7997 mL | 3.5994 mL |
| 10 mM | --- | --- | --- |
References
- [1] Shweta Joshi, et al. Macrophage Syk–PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk–PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Molecular Cancer Therapeutics. 2020.
- [2] Shweta Joshi, et al. Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Mol Cancer Ther. 2020 Mar;19(3):755-764.